The Japanese Journal of Dermatology
Online ISSN : 1346-8146
Print ISSN : 0021-499X
ISSN-L : 0021-499X
Original Articles
Safety and Efficacy of a Fixed-Dose Cyclosporin Microemulsion (100 mg) for the Treatment of Atopic Dermatitis
Yuki KoharaTomohiro TakeoChikatoshi KasugaiTakeshi YanagishitaYoichi AkitaDaisuke Watanabe
Author information

2013 Volume 123 Issue 9 Pages 1799-1806


Nineteen patients with severe atopic dermatitis, including 12 males and 7 females (ages: 21~73 year-old, body weight: 33~80 kg) visiting Aichi Medical University Hospital between October 2009 and February 2011, were enrolled in this study. Patients were given 100 mg cyclosporin microemulsion (Neoral®) once daily, regardless of their weight or skin condition, before breakfast. We assessed the Severity Classification of Atopic Dermatitis by the Japanese Dermatological Association (simple method), quality of life by Skindex16, itching and drowsiness by Visual Analog Scale (VAS), and the results of blood examinations, including peripheral blood eosinophil count, serum total IgE, lactate dehydrogenase (LDH), and thymus and activation-regulated chemokine (TARC) levels. In all patients, improvement of skin manifestations was achieved with 20~85% (average 63%) improvement of skin scores after 8 weeks of cyclosporin treatment and without any adverse side effects. Peripheral blood eosinophil count, LDH, and TARC levels were also decreased. When the patients were divided into two groups based on skin scores after treatment (less than 5 or 5 and more), rapid and significant reduction of serum TARC levels were observed in the improved group, indicating that serum TARC levels seem to be a good marker for effectiveness in this low-dose cyclosporine treatment of atopic dermatitis.

Information related to the author
© 2013 Japanese Dermatological Association
Previous article Next article